First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt remains negative
Q1 FY2026 short-term debt was $0, compared with $0 a year earlier.
Context
- Short-term debt amounted to 0.0% of total assets at the end of Q1 FY2026.
- Short-term debt increased in 0 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
Short-term Debt vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 short-term debt of $0 is the 7th highest of the 10 companies compared; the peer median is $369K.
- Short-term debt amounts to 0.0% of total assets for TRAX, versus a peer median of 0.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $2.12M | — | — | 0.6% | |
| Jun 2026 | $2.04M | — | — | 1.6% | |
| Jun 2026 | $641K | — | +7.2% | 0.3% | |
| Mar 2026 | $569K | — | — | 0.3% | |
| Mar 2026 | $369K | — | — | 0.3% | |
CLYMClimb Bio, Inc. | Mar 2026 | $263K | — | — | 0.2% |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $0 | — | — | 0.0% |
| Sep 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $369K | — | +7.2% | 0.3% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.